Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments involving multi-drug resistant (MDR), bacterial infections and rare diseases. Co.'s product candidate, Tebipenem Pivoxil Hydrobromide, is designed to be oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Co. is developing SPR720, an oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections. Co.'s platform, Potentiator Platform, that includes an IV-administered product candidate, SPR206 to treat MDR Gram-negative infection in the hospital. The SPRO stock yearly return is shown above.
The yearly return on the SPRO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SPRO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|